干扰素 beta-1a结构式
|
常用名 | 干扰素 beta-1a | 英文名 | interferon beta-1a |
|---|---|---|---|---|
| CAS号 | 145258-61-3 | 分子量 | N/A | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | N/A | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
| 中文名 | 干扰素 beta-1a |
|---|---|
| 英文名 | Interferonbeta1a/Humaninterferonbeta1a |
| 英文别名 | 更多 |
| 储存条件 | -70°C |
|---|
| RTECS号 | NM9701100 |
|---|
|
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
J. Neurol. Neurosurg. Psychiatr. 84(11) , 1186-91, (2013) To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.High density lipoprotein cholestero... |
|
|
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Drug Des. Devel. Ther. 6 , 175-86, (2012) Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial ... |
|
|
Emerging injectable therapies for multiple sclerosis.
Lancet Neurol. 12(11) , 1115-26, (2013) Available treatment options for relapsing-remitting multiple sclerosis (MS) have expanded in recent years, and several injectable therapies are under development. In this Rapid Review, we summarise em... |
| INTERFERON BETA-1A |
